Nanobiotix Sa ADR (NBTX) has released an update.
Nanobiotix Sa ADR, a biotech firm focused on cancer treatment enhancements, has reported significant operational progress in 2023, including a promising global agreement with Janssen for its novel radioenhancer NBTXR3. The company boasts strong financials with €75.3 million in cash reserves, extending its cash runway into Q3 2025, and anticipates multiple clinical readouts in 2024. These developments, coupled with a strengthened balance sheet through recent funding, position Nanobiotix to further advance NBTXR3’s potential in solid tumor therapies.
For further insights into NBTX stock, check out TipRanks’ Stock Analysis page.
